Reset filter
Mots-clés
SERDECHNAIA NEDOSTATOCHNOST' ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

495 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Eligibility Heart Failure, Congestive NCT00399594

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Effect of Targeting Left Ventricular Lead Position on the Rate of Response to Cardiac Resynchronization Therapy.; ODM derived from: https://clinicaltrials.gov/show/NCT00399594

Eligibility Heart Failure NCT00990665

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Promote Q Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Quartet Left Ventricular Heart Lead Study; ODM derived from: https://clinicaltrials.gov/show/NCT00990665

Eligibility Beta Blocker Intolerance; NCT02173028

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
RESynchronizaTiOn theRapy and bEta-blocker Titration; ODM derived from: https://clinicaltrials.gov/show/NCT02173028

Endpoint Hospitalisation for heart failure GSK study Chronic Coronary Heart Disease NCT00799903

- 20/09/2021 - 1 Formulaire, 3 Groupes Item, 43 Eléments de données, 1 Langue
Groupes Item: Investigator section, CEC Section, CEC Status
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Endpoint Hospitalisation for heart failure - Repeating form (Scheduled visits)

Eligibility Heart Failure NCT00918294

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
QuickOptTM Study - Using the QuickOptTM Method for Timing Cycle Optimization; ODM derived from: https://clinicaltrials.gov/show/NCT00918294

Eligibility Heart Failure NCT00795873

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
OVATIO CRT and SITUS OTW LV Lead Post Approval Study; ODM derived from: https://clinicaltrials.gov/show/NCT00795873

Swedish Heart Failure Registry (RiksSvikt) - SHFR Hospital

- 20/09/2021 - 1 Formulaire, 9 Groupes Item, 93 Eléments de données, 2 Langues
Groupes Item: Demography and Lifestyle, Patient self rated symptoms, Previous diseases, Performed procedures, Diagnostics, Biometrics and physical signs, Medication treatment, Patient and relative Information, Planned Follow-Up
Swedish Heart Failure Registry (RiksSvikt/SwedeHF) Sweden has a long tradition of measuring results and performance of the given health care. In order to stimulate to achieve better results, we try to find explanations for the discrepancies between different regions/hospitals/primary care units. In recent years, quality registries have become an increasingly important source of Swedish clinical research. SwedeHF (or RiksSvikt) was created in order to give the participating units knowledge, about how they diagnosed and treated their patients. The given information obtains indications where further efforts are needed in order to give patients with heart failure an optimal management. SwedeHF is an Internet-based registry, where participating units register their heart failure patient on-line, using transferred data from standardized forms or from computerized patients records. SHFR Hospital

Eligibility Congestive Heart Failure NCT00944125

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Dual Site Left Ventricular (LV) Pacing; ODM derived from: https://clinicaltrials.gov/show/NCT00944125

Eligibility Heart Failure at NYHA Stage III or IV NCT01126944

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 20 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
LVAD in Non Cardiac Transplant Candidates and Non Responders to Resynchronization; ODM derived from: https://clinicaltrials.gov/show/NCT01126944

Eligibility Heart Failure NCT02041130

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Renal Denervation in Heart Failure Patients With Preserved Ejection Fraction (RESPECT-HF); ODM derived from: https://clinicaltrials.gov/show/NCT02041130

Eligibility Heart Failure NCT02344199

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Eplerenone in Heart Failure Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT02344199

Eligibility Chronic Heart Failure NCT02322034

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Interval Training and Hormones in Chronic Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT02322034

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial